Introduction
============

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a frequently overlooked, serious disorder[@B1]. Its incidence is increasing according to recent reports in western countries and in Korea[@B2][@B3][@B4].

There are various well-defined risk factors of VTE, including recent major surgery, immobilization, cancer, old age, obesity, use of oral contraceptives, hormonal factors, a previous history of thrombosis, and inherited risk factors [@B5][@B6]. In addition to known risk factors, infectious disease and the associated systemic inflammatory response may increase thrombotic events of the venous system[@B7][@B8] caused by one or more of the three precipitants of venous thrombosis, as proposed by Virchow: venous stasis, hypercoagulability, and endothelial damage [@B9][@B10]. Several reports have documented that the risk of VTE was increased in patients with certain infectious conditions, such as cytomegalovirus, *Chlamydia pneumoniae*, human immunodeficiency virus (HIV), hepatitis C virus infection, and a recent respiratory tract infection[@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18]. Despite several reports of recent infection and VTE, its independent relationship is unclear, and clinical data regarding PE combined with infectious conditions are lacking. Therefore, the aim of the study was to evaluate the clinical characteristics and source of infection in patients with PE combined with infectious disease. And, the risk factor associated with combined infectious disease and its influence on mortality in patients with PE were assessed.

Materials and methods
=====================

1. Study design and population
------------------------------

Patients with PE found on computed tomography (CT) within 48 hours after admission were enrolled in this study. The study was conducted at regional university affiliated hospital (890 beds) between September 2010 and May 2014. Patients were excluded if they were admitted for pregnancy, preexisting PE or DVT, or were \<18 years of age. The diagnosis of PE was confirmed based on chest findings obtained using a 64-detector CT, including enhanced CT and CT pulmonary angiogram, scanner (Brilliance-64; Philips Medical Systems, Eindhoven, Netherlands). A pulmonary radiologist assessed the existence of thrombosis in the pulmonary artery. This study was approved by the hospital\'s institutional review board (No. GNUCH-2018-07-001). The need for informed consent was waived because of the retrospective nature of the study.

2. Data collection and clinical outcomes
----------------------------------------

We retrospectively investigated patients\' demographics, physiologic data, and laboratory data and the causes of infection, underlying diseases, and clinical outcomes. We divided patients into one of two groups based on information obtained from their medical charts: patients with PE combined with infectious disease or those with PE without infection. Patients\' characteristics were compared between those two groups, and between survivors and non-survivors. Finally, we analyzed the risk factors associated with combined infectious disease in PE patients and compared mortality between those two groups. And we assessed the factor associated non-survivors in patients with PE.

3. Definition
-------------

The definition of infection was based on microbiologic data and the patient\'s clinical course upon medical chart review. Infection was classified according to the Centers for Disease Control and Prevention\'s definitions[@B19].

4. Statistical analysis
-----------------------

Continuous variables are reported as the mean±standard deviation. Categorical variables are expressed as a number (%). Differences between the groups were statistically assessed using Student\'s t test or the chi-square test, as appropriate. Univariate and multivariate logistic regression analyses were performed to examine the risk factors for the development of infectious disease and mortality. A p-value of \<0.05 was considered statistically significant in all tests. All data were analyzed using SPSS version 22.0 for Window (IBM Corp., Armonk, NY, USA).

Results
=======

1. Patients\' characteristics
-----------------------------

Two hundred fifty-eight patients (male:female, 143:115; mean age, 68.2±13.0 years) were included. The most common symptom was dyspnea in up to 60% of patients, and 70 patients (26.9%) were asymptomatic. Twenty patients (7.7%) had a previous history of VTE, and 145 (55.8%) had an underlying malignant disease. One hundred seventy-one patients (65.8%) were older than 65 years, and 13 (5%) had a body mass index more than 30 kg/m^2^. Fifty-eight patients (22.3%) showed echocardiographic evidence of pulmonary hypertension, such as right ventricular hypokinesia or an increased pulmonary arterial pressure more than 20 mm Hg. The main pulmonary artery was involved in 88 patients (33.8%) based on CT findings. Thirty-seven patients (14.2%) died and the cause of death were underlying malignant disease in 27 patients (10.4%), uncontrolled infectious disease with multiorgan failure in six patients (2.3%), progression of underlying lung disease in three patients (1.1%), and heart failure in one patient ([Table 1](#T1){ref-type="table"}). Overall, 67 patients (25.9%) had a concomitant infectious disease. The infections involved the respiratory tract in 52 patients (77.6%), genitourinary tract in three (4.5%), hepatobiliary tract in three (4.5%), gastrointestinal tract in two (2.98%), bones and joints in three (4.5%), and other organ systems in four (5.4%) ([Table 2](#T2){ref-type="table"}).

2. Comparison of clinical characteristics in PE patients with infectious disease and without infection
------------------------------------------------------------------------------------------------------

The proportion of patients with dyspnea was greater among patients with PE combined with infectious disease than among those with PE without infection (76.1% vs. 53.9%, p\<0.05). The frequency of fever was more common in patients with PE combined with infectious disease than in those with PE without infection (17.9% vs. 6.2%, p\<0.05). The proportion of patients older than 65 years was higher among patients with PE combined with infectious disease than among those with PE without infection (77.6% vs. 61.7%, p\<0.05). The revised Geneva score[@B20] was not different between the two groups. The white blood cell count, serum C-reactive protein level, B-type natriuretic peptide level, and platelet count were significantly higher in patients with PE combined with infectious disease than in those with PE without underlying infection (p\<0.05). The D-dimer level was not significantly different between two groups. The frequency of main pulmonary artery involvement based on CT findings was not different between PE patients with infectious disease and without infection (28% and 22.4%, respectively). The sole segmental or subsegmental pulmonary artery involvement was also not different between PE patients with infectious disease and without infection (48.7% and 55.2%, respectively). In-hospital mortality was higher in patients with PE combined with infectious disease than in those with PE without infection (22.4% vs. 11.4%, p=0.006) ([Table 3](#T3){ref-type="table"}).

3. Factors associated with PE combined with infectious disease
--------------------------------------------------------------

In multivariate analysis, the results showed that underlying lung disease (odds ratio \[OR\], 3.69; 95% confidence interval \[CI\], 1.926--7.081; p\<0.001), bed-ridden state (OR, 2.84; 95% CI, 1.390--5.811; p=0.004), and malignant disease (OR, 1.867; 95% CI, 1.017--3.425; p=0.044) were associated with combined infectious disease in patients with PE ([Table 4](#T4){ref-type="table"}).

4. Comparison of clinical characteristics between survivors and non-survivors in patients with PE
-------------------------------------------------------------------------------------------------

The clinical characteristics and laboratory findings were compared between survivors and non-survivors in patients with PE ([Table 5](#T5){ref-type="table"}). The mean age and proportion of patients older than 65 years were higher in non-survivors than in survivors (p\<0.05). Clinical symptoms and signs were not different between the two groups. Bed-ridden state, underlying malignant and cerebrovascular diseases were more common in non-survivors than in survivors (p\<0.05). Combined infectious diseases were also common in non-survivors than in survivors (44.7% vs. 23.4%, p\<0.05). The troponin-I were higher in non-survivors than in survivors (p\<0.05). Radiologically, main pulmonary artery involvement was more common in non-survivors than in survivors (43.2% vs. 23.8%, p\<0.05). Right ventricular hypokinesia detected by echocardiography was also more common in non-survivors than in survivors (21.6% vs. 9.9%, p\<0.05).

5. Factors associated with non-survivors in patients with PE
------------------------------------------------------------

In multivariate analysis, the result showed that age \>65 years (OR, 2.575; 95% CI, 1.125--5.892; p=0.025), bed-ridden state (OR, 3.487; 95% CI, 1.397--8.703; p=0.007), malignant disease (OR, 9.275; 95% CI, 3.181--27.040; p\<0.001), main pulmonary artery involvement (OR, 3.032; 95% CI, 1.283--7.162; p=0.011), and concomitant infectious disease (OR, 4.189; 95% CI, 1.692--10.372; p=0.002) were associated with non-survivors in patients of PE ([Table 6](#T6){ref-type="table"}).

Discussion
==========

This study showed that a substantial portion of patients with PE had concomitant infectious disease. The underlying lung disease, bed-ridden state and malignant disease were independent risk factor for PE with combined infectious disease and presence of infectious disease may contribute mortality in patients with PE.

Several reports have shown that various infectious conditions were associated with the development of VTE, and overall, 11%--26% of patients with VTE may have an underlying acute infectious conditions[@B21][@B22][@B23][@B24][@B25]. For example, cytomegalovirus antigen positivity was significantly higher in patients with VTE than in age-matched and sex-matched controls[@B13]. Additionally, in 312,147 patients with inflammatory bowel disease, the presence of VTE was 2-fold higher in patients with *Clostridium difficile* infection (CDI) than in those without CDI[@B26]. It has been also demonstrated that HIV infection and hepatitis virus infection are associated with an increased risk of VTE[@B11][@B12]. In a review of a primary care database of 11,557 cases of first-time PE or VTE, Clayton et al.[@B27] reported that a preceding respiratory infection may increase the risk of PE or VTE by more than 2.5-folds for up to a year. A prospective study of 5,451 patients with ultrasound-confirmed DVT showed that beside known risk factors, osteoarthritis, pneumonia, sepsis, and other infectious diseases were present in more than 30% of patients1. In addition, in acutely ill, hospitalized, general medical patients, the presence of acute infectious diseases was significantly associated with an increased risk of VTE (relative risk, 1.47)[@B24]. Moreover, the epidemiologic study, a case control study involving patients with a first documented VTE and controls subjects, influenza vaccination during the previous 12 months reduced the risk of VTE by about 50% in those younger than 52 years and had a similar effect on DVT and PE[@B28]. Further, when heparin was routinely administered in hospital-admitted patients with underlying infectious disease, the occurrence of non-thromboembolic events was significantly lower in these patients with various infectious diseases than in control patients with infectious diseases[@B22].

However, it is unclear whether the infection itself increases the risk of developing VTE or whether secondary problems, such as immobility caused by infection, increase the incidence of VTE. Although the mechanism was not elucidated here, there are possible explanations for the mechanism underlying infection and VTE. Acute infectious processes may cause endothelial injury, promoting the genesis of thrombosis in the venous system, which is usually much more vulnerable to stasis than is arterial blood. From experimental study, endothelial dysfunction in vein of healthy volunteer exposed to endotoxin may increase the risk of developing cardiovascular thromboticevent[@B10].

Respiratory tract infection was the most common cause of infection in the present study. Cohoon et al.[@B29] reported that genitourinary and lower respiratory tract infection was the most common infections in their study. They also reported a relatively higher risk of VTE in intra-abdominal infection and blood stream infection. This is a reason why patients with lower respiratory tract infection often undergo chest CT for evaluation of the disease. Thus, PE may be detected incidentally by chest CT. The increasing incidence of chest CT is often correlated with an increasing incidence of PE, indicating that PE is incidentally detected by chest CT [@B30][@B31]. In this study, over two-thirds patients were diagnosed in chest CT, not embolism CT. It may indicate that PE is incidentally detected in clinical practice.

As expected, patients with PE combined with infectious conditions had a poor outcome, resulting in a higher mortality in these patients. This has not been reported previously. Other factors associated with an increased risk of mortality, such as older age, malignant disease, right ventricular dysfunction, and immobilization [@B32][@B33], were similar to those identified in our study. Additionally, main pulmonary artery involvement is associated with a poor short-term outcome in patients with PE[@B34].

This study has a several limitations. First, because of the study\'s retrospective design, infectious disease could not be clearly classified based on the medial record review and the exact incidence of infectious disease couldn\'t estimate from this study in all PE patients. Second, some proportion of patients with PE was incidentally detected by chest CT for evaluating respiratory tract infection. So, other infectious disease like intraabdominal and genitourinary tract infection may be underestimated. Third, most of patients had a severe underlying disease which may significantly contribute mortality in these patients. The adjustment of severe underlying disease needed to exact contribution of infectious disease to mortality in patients with PE.
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###### Clinical characteristics of enrolled patients with PE

![](trd-83-157-i001)

  Clinical characteristic                        Value (n=258)
  ---------------------------------------------- ---------------
  Demographics                                   
   Age, yr                                       68.2±13.0
   Age \>65 yr                                   171 (66.3)
   Male sex                                      143 (55.4)
   BMI (n=233)                                   22.76±3.9
   BMI \>30 kg/m^2^                              13 (5.0)
   Current smoking history                       17 (6.5)
  Clinical symptoms and signs                    
   Dyspnea                                       155 (60.0)
   Hemoptysis                                    10 (3.8)
   Fever                                         24 (9.3)
   Chest pain                                    37 (14.3)
   Lower leg edema                               29 (11.2)
   Syncope                                       3 (1.2)
   Hypotension                                   15 (5.8)
   Asymptomatic                                  70 (27.1)
   Revised Geneva score                          6.0±1.6
   Died                                          37 (14.3)
  Risk factors                                   
   History of recent operation (\<3 mo)          67 (25.9)
   Previous history of VTE                       20 (7.7)
   Presence of infectious disease                67 (25.9)
   Bed-ridden state                              51 (19.7)
  Comorbidities                                  
   Malignant disease                             145 (56.2)
   Cerebrovascular disease                       30 (11.6)
   Lung disease                                  64 (24.8)
   Heart disease                                 9 (3.5)
   Liver disease                                 14 (5.4)
   Kidney disease                                8 (3.1)
   Diabetes                                      56 (21.7)
   Hypertension                                  85 (32.9)
   Autoimmune disease                            3 (1.2)
  Laboratory findings                            
   WBC, mm^3^/L                                  10.6±27.8
   Platelet, mm^3^/L                             239.2±111.5
   CRP, mg/L                                     51.1±62.7
   D-dimer, μg/mL (n=195)                        6.6±6.3
   BNP, pg/mL (n=147)                            332.7±440.0
   Troponin-I, ng/mL (n=155)                     1.0±9.1
   CK-MB (n=158)                                 3.5±3.8
   Fibrinogen, mg/dL (n=138)                     393.4±165.7
   AT III, mg/dL (n=89)                          89.4±39.4
   Homocysteine, μmol/L (n=41)                   9.3±5.6
  Radiologic findings                            
   Norma chest X-ray                             121 (46.8)
   Involvement of pulmonary artery on chest CT   
   Main pulmonary artery, right                  52 (20.2)
   Main pulmonary artery, left                   39 (15.1)
   Interlobar artery, right                      103 (39.9)
   Interlobar artery, left                       69 (26.7)
   Segmental artery, right                       158 (61.2)
   Segmental artery, left                        95 (36.8)
   Subsegmental artery, right                    88 (34.1)
   Subsegmental artery, left                     51 (19.7)
  Echocardiographic finding (n=164)              
   Pulmonary hypertension                        58 (22.4)
   Right ventricular hypokinesia                 30 (11.6)

Values are presented as mean±SD or number (%).

BMI: body mass index; VTE: venous thromboembolism; WBC: white blood cell; CRP: C-reactive protein; BNP: B-type natriuretic peptide; CK-MB: creatine kinase-muscle/brain; AT: antithrombin; CT: computerized tomography.

###### The site and cause of infection in patients with pulmonary embolism combined with infectious disease
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  Cause of infection                 No. (%) (n=67)
  ---------------------------------- ----------------
  Respiratory tract infection        52 (77.6)
   Pneumonia                         44 (65.6)
   Acute bronchiolitis               4 (5.9)
   Pulmonary tuberculosis            4 (5.9)
  Genitourinary tract infection      3 (4.4)
  Hepatobiliary tract infection      3 (4.4)
   Acute cholecystitis               1 (1.5)
   Acute pancreatitis                1 (1.5)
   Perihepatic abscess               1 (1.5)
  Gastrointestinal tract infection   2 (2.9)
   Ischemic colitis                  2 (2.9)
  Bone and joint infection           3 (4.4)
   Osteomyelitis of spine            3 (4.4)
  Skin and soft tissue infection     2 (2.9)
   Shoulder abscess                  1 (1.5)
   Necrotizing fasciitis             1 (1.5)
  Miscellaneous infection            2 (2.9)
   Infective endocarditis            1 (1.5)
   Tuberculous pericarditis          1 (1.5)

###### Comparison of clinical characteristics in patients with PE combined with infectious disease and in patients with PE without infection
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  Variable                                                 Combined with infectious disease (n=67)   Not combined with infection (n=191)   p-value
  -------------------------------------------------------- ----------------------------------------- ------------------------------------- ---------
  Demographics                                                                                                                             
   Age, yr                                                 71.6±12.2                                 67.2±13.2                             0.028
   Age \>65 yr                                             52 (77.6)                                 119 (62.3)                            0.018
   Male sex                                                21 (31.3)                                 122 (63.9)                            0.972
   BMI (n=233)                                             21.8±4.2                                  23.1±3.7                              0.053
   BMI \>30 kg/m^2^                                        4 (6.0)                                   9 (4.7)                               0.458
   Current smoking history                                 1 (1.5)                                   16 (8.3)                              0.208
  Clinical symptoms and signs                                                                                                              
   Dyspnea                                                 51 (76.1)                                 104 (54.4)                            0.002
   Hemoptysis                                              4 (6.0)                                   6 (3.1)                               0.294
   Fever                                                   12 (17.9)                                 12 (6.2)                              0.004
   Chest pain                                              7 (10.4)                                  30 (15.7)                             0.304
   Lower leg edema                                         7 (10.4)                                  22 (11.5)                             0.831
   Syncope                                                 0 (0)                                     3 (1.6)                               0.305
   Hypotension                                             3 (4.5)                                   12 (6.2)                              0.599
   Asymptomatic                                            15 (22.4)                                 55 (28.8)                             0.331
   Revised Geneva score                                    5.9±1.6                                   6.1±1.5                               0.302
   Died                                                    15 (22.4)                                 22 (11.5)                             0.027
  Risk factors                                                                                                                             
   History of recent operation (\<3 mo)                    7 (10.4)                                  20 (10.4)                             0.458
   Previous history of VTE                                 5 (7.5)                                   15 (7.8)                              0.497
   Bed-ridden state                                        21 (31.3)                                 30 (15.7)                             0.001
  Comorbidities                                                                                                                            
   Malignant disease                                       27 (40.3)                                 98 (51.3)                             0.343
   Cerebrovascular disease                                 12 (17.9)                                 18 (9.4)                              0.012
   Lung disease                                            39 (58.2)                                 25 (13.1)                             0.001
   Heart disease                                           9 (13.4)                                  29 (15.1)                             0.103
   Liver disease                                           5 (7.5)                                   9 (4.7)                               0.451
   Kidney disease                                          3 (4.5)                                   6 (3.1)                               0.454
   Diabetes                                                12 (17.9)                                 44 (23.0)                             0.402
   Hypertension                                            16 (23.9)                                 69 (36.1)                             0.074
   Autoimmune disease                                      2 (3.0)                                   1 (0.5)                               0.164
  Laboratory findings                                                                                                                      
   WBC, mm^3^/L                                            16.4±54.0                                 8.6±5.4                               0.048
   Platelet, mm^3^/L                                       269.3±115.4                               228.7±108.4                           0.013
   CRP, mg/L                                               69.1±63.0                                 44.9±61.7                             0.008
   D-dimer, μg/mL (n=195)                                  5.9±5.9                                   6.9±6.5                               0.299
   BNP, pg/mL (n=147)                                      445.8±543.7                               275.0±366.3                           0.025
   Troponin-I, ng/mL (n=155)                               0.3±1.2                                   1.3 ±11.0                             0.521
   CK-MB (n=158)                                           3.9±4.4                                   3.4±3.6                               0.496
   Fibrinogen, mg/dL (n=138)                               435.6±190.1                               380.7±156.5                           0.143
   AT III, mg/dL (n=89)                                    79.8±23.2                                 92.1±42.5                             0.099
   Homocysteine, μmol/L (n=41)                             6.5±3.6                                   10.1±5.9                              0.042
  Radiologic findings                                                                                                                      
   Norma chest X-ray                                       22 (32.8)                                 99 (51.8)                             0.009
   Main pulmonary artery involvement                       15 (22.4)                                 54 (28.3)                             0.372
   Isolated segmental or subsegmental artery involvement   37 (55.2)                                 94 (49.2)                             0.358
  Echocardiographic finding (n=164)                                                                                                        
   Pulmonary hypertension                                  17 (25.4)                                 41 (21.4)                             0.484
   Right ventricular hypokinesia                           6 (9.0)                                   24 (12.5)                             0.442

Values are presented as mean±SD or number (%).

PE: pulmonary embolism; BMI: body mass index; VTE: venous thromboembolism; WBC: white blood cell; CRP: C-reactive protein; BNP: B-type natriuretic peptide; CK-MB: creatine kinase-muscle/brain; AT: antithrombin.

###### Factor associated with infectious disease in patients with PE
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  Variable                  Univariate analysis   Multivariate analysis                                    
  ------------------------- --------------------- ----------------------- --------- ------- -------------- -------
  Age \>65 yr               2.15                  1.133--4.103            0.019     1.922   0.977--3.779   0.058
  BMI \>30 kg/m^2^          1.27                  0.378--4.268            0.699     \-      \-             \-
  Bed-ridden state          2.48                  1.299--4.735            0.006     2.842   1.390--5.811   0.004
  Lung disease              3.44                  1.879--6.317            \<0.001   3.693   1.926--7.081   0.000
  Cerebrovascular disease   2.12                  0.964--4.672            0.062     \-      \-             \-
  Malignant disease         2.331                 1.321--4.111            0.003     1.867   1.017--3.425   0.044
  Kidney disease            1.043                 0.205--5.296            0.960     \-      \-             \-
  Liver disease             1.649                 0.532--5.106            0.386     \-      \-             \-
  Diabetes                  1.353                 0.666--2.751            0.403     \-      \-             \-

PE: pulmonary embolism; OR: odds ratio; CI: confidence interval; BMI: body mass index.

###### Comparison of clinical characteristics between survivors and non-survivors in patients with PE
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  Variable                                                 Survivors (n=221)   Non-survivors (n=37)   p-value
  -------------------------------------------------------- ------------------- ---------------------- ---------
  Demographics                                                                                        
   Age, yr                                                 62.0±15.4           69.3±12.3              0.002
   Male sex                                                122 (55.2)          21 (56.8)              0.817
   Age \>65 yr                                             155 (70.1)          16 (43.2)              0.002
   BMI (n=233)                                             22.8±3.9            22.1±3.9               0.333
   BMI \>30 kg/m^2^                                        12 (5.4)            1 (2.7)                0.552
   Current smoking history                                 17 (7.6)            0 (0)                  0.316
  Clinical symptoms and signs                                                                         
   Dyspnea                                                 129 (58.3)          26 (70.3)              0.154
   Hemoptysis                                              9 (4.0)             1 (2.7)                0.696
   Fever                                                   19 (8.5)            5 (13.5)               0.331
   Chest pain                                              31 (14.0)           6 (16.2)               0.709
   Lower leg edema                                         19 (8.5)            10 (27.0)              0.001
   Syncope                                                 3 (1.3)             0 (0)                  0.478
   Hypotension                                             11 (5.0)            4 (10.8)               0.156
   Asymptomatic                                            63 (28.5)           7 (18.9)               0.236
   Revised Geneva score                                    6.0±1.5             6.2±1.4                0.655
  Risk factors                                                                                        
   History of recent operation (\<3 mo)                    22 (9.9)            2 (5.4)                0.458
   Previous history of VTE                                 15 (6.8)            5 (13.2)               0.186
   Bed-ridden state                                        38 (17.1)           13 (35.1)              0.010
  Comorbidities                                                                                       
   Malignant disease                                       114 (51.5)          31 (83.8)              \<0.001
   Cerebrovascular disease                                 27 (12.2)           3 (8.1)                0.481
   Lung disease                                            53 (23.9)           11 (29.7)              0.436
   Heart disease                                           37 (16.7)           3 (7.9)                0.225
   Liver disease                                           12 (5.4)            2 (5.4)                0.995
   Kidney disease                                          5 (2.2)             3 (8.1)                0.454
   Diabetes                                                48 (21.7)           8 (21.6)               0.989
   Hypertension                                            70 (31.6)           15 (40.5)              0.272
   Autoimmune disease                                      3 (1.3)             0                      0.478
   Infectious disease                                      52 (23.5)           15 (40.5)              0.027
  Laboratory findings                                                                                 
   WBC, mm^3^/L                                            10,521±3,001        11,197±6,334           0.765
   Platelet, mm^3^/L                                       244,257±11,322      209,354±96,246         0.052
   CRP, mg/L                                               48.3±62.8           68.3±60.7              0.073
   D-dimer, μg/mL (n=195)                                  6.69±6.29           6.75±6.65              0.964
   BNP, pg/mL (n=147)                                      317.5±431.4         442.9±497.5            0.320
   Troponin-I, ng/mL (n=155)                               0.30±0.99           5.3±24.28              0.018
   CK-MB (n=158)                                           3.72±3.99           2.54±2.57              0.70
   Fibrinogen, mg/dL (n=138)                               392.4±167.4         398.59±160.7           0.871
   AT III, mg/dL (n=89)                                    92.2±41.1           73.61±22.4             0.023
   Homocysteine, μmol/L (n=41)                             9.4±5.7             7.2±3.0                0.476
  Radiologic findings                                                                                 
   Norma chest X-ray                                       111 (49.8)          10 (27.0)              0.010
   Main pulmonary artery involvement                       53 (23.8)           16 (43.2)              0.013
   Isolated segmental or subsegmental artery involvement   113 (50.7)          18 (48.6)              0.820
  Echocardiographic finding (n=164)                                                                   
   Pulmonary hypertension                                  49 (22.0)           9 (24.3)               0.750
   Right ventricular hypokinesia                           22 (9.9)            8 (21.6)               0.038

Values are presented as mean±SD or number (%).

PE: pulmonary embolism; BMI: body mass index; VTE: venous thromboembolism; WBC: white blood cell; CRP: C-reactive protein; BNP: B-type natriuretic peptide; CK-MB: creatine kinase-muscle/brain; AT: antithrombin.

###### Factors associated with non-survivors in patients with PE
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  Variable                            Univariate analysis   Multivariate analysis                                   
  ----------------------------------- --------------------- ----------------------- ------- ------- --------------- -------
  Age \>65 yr                         2.992                 1.471--6.086            0.002   2.575   1.125--5.892    0.025
  BMI \>30 kg/m^2^                    2.087                 0.263--16.547           0.486   \-      \-              \-
  Bed-ridden state                    2.637                 1.233--5.638            0.012   3.487   1.397--8.703    0.007
  Lung disease                        1.357                 0.629--2.929            0.437   \-      \-              \-
  Cerebrovascular disease             1.561                 0.449--5.434            0.484   \-      \-              \-
  Malignant disease                   4.940                 1.983--12.306           0.001   9.275   3.181--27.040   0.000
  Kidney disease                      3.847                 0.879--16.837           0.074   \-      \-              \-
  Liver disease                       1.005                 0.216--4.683            0.995   \-      \-              \-
  Diabetes                            1.006                 0.432--2.342            0.989   \-      \-              \-
  Infectious disease                  2.242                 1.085--4.634            0.029   4.189   1.692--10.372   0.002
  Hypotension                         2.336                 0.702--7.769            0.166   \-      \-              \-
  Troponin-I                          1.045                 0.958--1.141            0.319   \-      \-              \-
  Main pulmonary artery involvement   2.444                 1.190--5.020            0.015   3.032   1.283--7.162    0.011
  Right ventricular hypokinesia       2.520                 1.027--6.187            0.044   1.997   0.696--5.735    0.199

PE: pulmonary embolism; OR: odds ratio; CI: confidence interval; BMI: body mass index.
